Ein Paarvergleich findet Originalpassagen, die den anderen Wirkstoff wörtlich nennen. Aussagen gelten für das jeweilige Präparat und seine Formulierung. Klassenbegriffe und abweichende Synonyme können fehlen. Kein Treffer bedeutet nicht, dass keine Wechselwirkung besteht.
RxNorm 05-Oct-2026 · geprüft 2026-10-25 · 1009 Präparate · 54812 Quellenpassagen · 148 strukturierte Aussagen. Automatisch aktualisiert, ohne menschliche Freigabe.
Nebenwirkungen · Dupixent
Dupixent 300 mg solution for injection in pre-filled syringe Dupixent 300 mg solution for injection in pre-filled pen · Abschnitt 4.8 · PDF-Seite 11–12
HOS-138343 · Präparat HOS-098186
11
Eczema herpeticum
Eczema herpeticum was reported in < 1% of the dupilumab groups and in < 1 % of the placebo group
in the 16-week atopic dermatitis monotherapy adult studies. In the 52-week atopic dermatitis
dupilumab + TCS adult study, eczema herpeticum was reported in 0.2 % of the dupilumab + TCS
group and 1.9 % of the placebo + TCS group. These rates remained stable at 5 years in the long-term
OLE study (AD-1225).
Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.
Vollständigen Kontext in der EMA-Fachinformation lesen →Quellennachweis
Version 2026-08-18T10:31:00Z · SHA-256 03cfef0820960157937161ad51a96760d9bff76c2f23c8cca9d5128db312db79 · Passage e00c389a4c36fbd2553e573cbfebbb57af723b1e671a56f50664e2949af82deb · Zeichen 4625–5049 im Abschnitt
Nebenwirkungen · Dupixent
Dupixent 300 mg solution for injection in pre-filled syringe Dupixent 300 mg solution for injection in pre-filled pen · Abschnitt 4.8 · PDF-Seite 12
HOS-138344 · Präparat HOS-098186
Eosinophilia
Dupilumab-treated patients had a greater mean initial increase from baseline in eosinophil count
compared to patients treated with placebo in the atopic dermatitis, asthma, CRSwNP, COPD and CSU
indications. Eosinophil counts declined to near baseline levels during study treatment and returned to
baseline during the asthma open-label extension safety study (TRAVERSE). The mean blood
eosinophil levels decreased to below baseline by week 20 and was maintained up to 5 years in the
long-term OLE study (AD-1225). Compared to placebo, no increase in mean blood eosinophil counts
was observed in PN (PRIME and PRIME2). Mean and median blood eosinophil counts declined to
near baseline or remained below baseline levels in EoE and COPD (BOREAS and NOTUS) during
study treatment.
Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.
Vollständigen Kontext in der EMA-Fachinformation lesen →Quellennachweis
Version 2026-08-18T10:31:00Z · SHA-256 03cfef0820960157937161ad51a96760d9bff76c2f23c8cca9d5128db312db79 · Passage 1f74eae6c70517aa0cf3e1b8636635a9d36c2554b8bd3efd0149b0c3845098f3 · Zeichen 5051–5839 im Abschnitt
Nebenwirkungen · Dupixent
Dupixent 300 mg solution for injection in pre-filled syringe Dupixent 300 mg solution for injection in pre-filled pen · Abschnitt 4.8 · PDF-Seite 12
HOS-138345 · Präparat HOS-098186
Treatment-emergent eosinophilia (≥ 5,000 cells/mcL) was observed in < 3 % of dupilumab-treated
patients and < 0.5 % in placebo-treated patients (SOLO1, SOLO2, AD-1021, DRI12544, QUEST, and
VOYAGE; SINUS-24 and SINUS-52, PRIME, and PRIME2 studies; TREET Parts A and B;
BOREAS and NOTUS; CUPID Study A, B, and C.)
Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.
Vollständigen Kontext in der EMA-Fachinformation lesen →Quellennachweis
Version 2026-08-18T10:31:00Z · SHA-256 03cfef0820960157937161ad51a96760d9bff76c2f23c8cca9d5128db312db79 · Passage 9c796f69f648d0895641bb1298ef887c91059b5becd19609da5d51f670f329a6 · Zeichen 5842–6153 im Abschnitt
Nebenwirkungen · Dupixent
Dupixent 300 mg solution for injection in pre-filled syringe Dupixent 300 mg solution for injection in pre-filled pen · Abschnitt 4.8 · PDF-Seite 12
HOS-138346 · Präparat HOS-098186
Treatment-emergent eosinophilia (≥5,000 cells/mcL) was observed in 8.4% of dupilumab-treated
patients and 0% in placebo-treated patients in study AD-1539, with median eosinophil counts
declining below baseline at end of treatment period.
Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.
Vollständigen Kontext in der EMA-Fachinformation lesen →Quellennachweis
Version 2026-08-18T10:31:00Z · SHA-256 03cfef0820960157937161ad51a96760d9bff76c2f23c8cca9d5128db312db79 · Passage 3a4d07c86543c24b2cc15acb703ee12310b2d2ae86c9c52b9e4b305cdcd55e7c · Zeichen 6155–6392 im Abschnitt
Nebenwirkungen · Dupixent
Dupixent 300 mg solution for injection in pre-filled syringe Dupixent 300 mg solution for injection in pre-filled pen · Abschnitt 4.8 · PDF-Seite 12
HOS-138347 · Präparat HOS-098186
Infections
In the 16-week atopic dermatitis monotherapy clinical adult studies, serious infections were reported in
1.0 % of patients treated with placebo and 0.5 % of patients treated with dupilumab. In the 52-week
atopic dermatitis CHRONOS adult study, serious infections were reported in 0.6 % of patients treated
with placebo and 0.2 % of patients treated with dupilumab. The rates of serious infections remained
stable at 5 years in the long-term OLE study (AD-1225).
Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.
Vollständigen Kontext in der EMA-Fachinformation lesen →Quellennachweis
Version 2026-08-18T10:31:00Z · SHA-256 03cfef0820960157937161ad51a96760d9bff76c2f23c8cca9d5128db312db79 · Passage 785537183d75d014119b60110c648c7da8cbbbc6e4c160d7c61ac8e90e0c415b · Zeichen 6394–6866 im Abschnitt
Nebenwirkungen · Dupixent
Dupixent 300 mg solution for injection in pre-filled syringe Dupixent 300 mg solution for injection in pre-filled pen · Abschnitt 4.8 · PDF-Seite 12
HOS-138348 · Präparat HOS-098186
No increase was observed in the overall incidence of infections with dupilumab compared to placebo
in the safety pool for asthma clinical studies. In the 24-week safety pool, serious infections were
reported in 1.0% of patients treated with dupilumab and 1.1% of patients treated with placebo. In the
52-week QUEST study, serious infections were reported in 1.3% of patients treated with dupilumab
and 1.4% of patients treated with placebo.
Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.
Vollständigen Kontext in der EMA-Fachinformation lesen →Quellennachweis
Version 2026-08-18T10:31:00Z · SHA-256 03cfef0820960157937161ad51a96760d9bff76c2f23c8cca9d5128db312db79 · Passage 94f006dbb52337a7af509c64335336d461b681b1fe9a500531e4a4744940bce4 · Zeichen 6868–7308 im Abschnitt
Nebenwirkungen · Dupixent
Dupixent 300 mg solution for injection in pre-filled syringe Dupixent 300 mg solution for injection in pre-filled pen · Abschnitt 4.8 · PDF-Seite 12
HOS-138349 · Präparat HOS-098186
No increase was observed in the overall incidence of infections with dupilumab compared to placebo
in the safety pool for CRSwNP clinical studies. In the 52-week SINUS-52 study, serious infections
were reported in 1.3 % of patients treated with dupilumab and 1.3 % of patients treated with placebo.
Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.
Vollständigen Kontext in der EMA-Fachinformation lesen →Quellennachweis
Version 2026-08-18T10:31:00Z · SHA-256 03cfef0820960157937161ad51a96760d9bff76c2f23c8cca9d5128db312db79 · Passage 773ec9849a4e91485b454a690ad2693e70b9176db1570d864cd8446e2cde27bb · Zeichen 7310–7608 im Abschnitt
Nebenwirkungen · Dupixent
Dupixent 300 mg solution for injection in pre-filled syringe Dupixent 300 mg solution for injection in pre-filled pen · Abschnitt 4.8 · PDF-Seite 12
HOS-138350 · Präparat HOS-098186
No increase was observed in the overall incidence of infections with dupilumab compared to placebo
in the safety pool for PN clinical studies. In the safety pool, serious infections were reported in 1.3% of
patients treated with dupilumab and 1.3% of patients treated with placebo.
Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.
Vollständigen Kontext in der EMA-Fachinformation lesen →Quellennachweis
Version 2026-08-18T10:31:00Z · SHA-256 03cfef0820960157937161ad51a96760d9bff76c2f23c8cca9d5128db312db79 · Passage f96400e42c417e0252cfc280202c69557b45444b01ecf76256b79ff3f7d3f1ff · Zeichen 7610–7891 im Abschnitt
Nebenwirkungen · Dupixent
Dupixent 300 mg solution for injection in pre-filled syringe Dupixent 300 mg solution for injection in pre-filled pen · Abschnitt 4.8 · PDF-Seite 12
HOS-138351 · Präparat HOS-098186
The overall incidence of infections was numerically higher with dupilumab (32.0%) compared to
placebo (24.8%) in the 24-week safety pool for the EoE TREET (Parts A and B) studies. The overall
incidence of infections was numerically higher in placebo (41.2%) compared to dupilumab (35.8%) in
the EoE KIDS (Part A) study. In the 24-week safety pool for the EoE TREET (Parts A and B) studies,
serious infections were reported in 0.5% of patients treated with dupilumab and 0% of patients treated
with placebo. No serious infections were reported in EoE KIDS (Part A) study. Upper respiratory tract
infections composed of several terms, including, but not limited to, COVID-19, sinusitis, and upper
Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.
Vollständigen Kontext in der EMA-Fachinformation lesen →Quellennachweis
Version 2026-08-18T10:31:00Z · SHA-256 03cfef0820960157937161ad51a96760d9bff76c2f23c8cca9d5128db312db79 · Passage 6f7458091ce618a5d544a8c78d00c3ff111acdaa8d611fe9ad3e6c46191534f8 · Zeichen 7893–8587 im Abschnitt
Nebenwirkungen · Dupixent
Dupixent 300 mg solution for injection in pre-filled syringe Dupixent 300 mg solution for injection in pre-filled pen · Abschnitt 4.8 · PDF-Seite 12–13
HOS-138352 · Präparat HOS-098186
12
respiratory tract infection was numerically higher with dupilumab (17.2%) compared to placebo (10.3%)
in EoE TREET (Parts A and B), and with dupilumab (26.9%) compared to placebo (20.6%) in EoE
KIDS (Part A) study.
Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.
Vollständigen Kontext in der EMA-Fachinformation lesen →Quellennachweis
Version 2026-08-18T10:31:00Z · SHA-256 03cfef0820960157937161ad51a96760d9bff76c2f23c8cca9d5128db312db79 · Passage 7f79386ae64b16362266466e97fabd9658ce89bb6a1c58012bff314060889c3b · Zeichen 8640–8858 im Abschnitt
Nebenwirkungen · Dupixent
Dupixent 300 mg solution for injection in pre-filled syringe Dupixent 300 mg solution for injection in pre-filled pen · Abschnitt 4.8 · PDF-Seite 13
HOS-138353 · Präparat HOS-098186
No increase was observed in the overall incidence of infections with dupilumab compared to placebo
in the safety pool for COPD clinical studies. Serious infections were reported in 4.9% of patients
treated with dupilumab and 4.8% of patients treated with placebo.
Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.
Vollständigen Kontext in der EMA-Fachinformation lesen →Quellennachweis
Version 2026-08-18T10:31:00Z · SHA-256 03cfef0820960157937161ad51a96760d9bff76c2f23c8cca9d5128db312db79 · Passage cb15d2994da5255b048ece7f1ba576c82ca8b581391136ad7a32f446cbd4860f · Zeichen 8860–9123 im Abschnitt
Nebenwirkungen · Dupixent
Dupixent 300 mg solution for injection in pre-filled syringe Dupixent 300 mg solution for injection in pre-filled pen · Abschnitt 4.8 · PDF-Seite 13
HOS-138354 · Präparat HOS-098186
In the safety pool for CUPID studies (A, B, and C) no increase was observed in the overall incidence
of infections with dupilumab compared to placebo. In the safety pool, serious infections were observed
in 0.5% of patients treated with dupilumab and 0.5% of patients treated with placebo. No serious
infections were observed in children treated with dupilumab in the PKM16982 study.
Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.
Vollständigen Kontext in der EMA-Fachinformation lesen →Quellennachweis
Version 2026-08-18T10:31:00Z · SHA-256 03cfef0820960157937161ad51a96760d9bff76c2f23c8cca9d5128db312db79 · Passage a5dd26a521f4ae63005cb225c66014cb6f920cb01bdf610984f78026f63698d9 · Zeichen 9125–9508 im Abschnitt
Nebenwirkungen · Dupixent
Dupixent 300 mg solution for injection in pre-filled syringe Dupixent 300 mg solution for injection in pre-filled pen · Abschnitt 4.8 · PDF-Seite 13
HOS-138355 · Präparat HOS-098186
Immunogenicity
As with all therapeutic proteins, there is a potential for immunogenicity with dupilumab.
Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.
Vollständigen Kontext in der EMA-Fachinformation lesen →Quellennachweis
Version 2026-08-18T10:31:00Z · SHA-256 03cfef0820960157937161ad51a96760d9bff76c2f23c8cca9d5128db312db79 · Passage b163642c91425432a669b3b3741c3c0bedff5a6ab006f9500e083446890d4aae · Zeichen 9510–9614 im Abschnitt
Nebenwirkungen · Dupixent
Dupixent 300 mg solution for injection in pre-filled syringe Dupixent 300 mg solution for injection in pre-filled pen · Abschnitt 4.8 · PDF-Seite 13
HOS-138356 · Präparat HOS-098186
Antidrug Antibodies (ADA) responses were not generally associated with impact on dupilumab
exposure, safety, or efficacy.
Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.
Vollständigen Kontext in der EMA-Fachinformation lesen →Quellennachweis
Version 2026-08-18T10:31:00Z · SHA-256 03cfef0820960157937161ad51a96760d9bff76c2f23c8cca9d5128db312db79 · Passage 1914a979fb299824649e191d536fe76a47ea2a5aa8cc84094d74d1763b8ea6e2 · Zeichen 9616–9737 im Abschnitt
Nebenwirkungen · Dupixent
Dupixent 300 mg solution for injection in pre-filled syringe Dupixent 300 mg solution for injection in pre-filled pen · Abschnitt 4.8 · PDF-Seite 13
HOS-138357 · Präparat HOS-098186
Approximately 5 % of patients with atopic dermatitis, asthma, or CRSwNP who received dupilumab
300 mg Q2W for 52 weeks developed ADA to dupilumab; approximately 2 % exhibited persistent
ADA responses and approximately 2 % had neutralizing antibodies. Similar results were observed in
adult patients with PN who received dupilumab 300 mg Q2W for 24 weeks, paediatric patients (6
months to 11 years of age) with atopic dermatitis who received either dupilumab 200 mg Q2W, 200
mg Q4W, or 300 mg Q4W for 16 weeks and patients (6 to 11 years of age) with asthma who received
dupilumab 100 mg Q2W or 200 mg Q2W for 52 weeks. Similar ADA responses were observed in
adult patients with atopic dermatitis treated with dupilumab for up to 5 years in the long-term OLE
study (AD-1225).
Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.
Vollständigen Kontext in der EMA-Fachinformation lesen →Quellennachweis
Version 2026-08-18T10:31:00Z · SHA-256 03cfef0820960157937161ad51a96760d9bff76c2f23c8cca9d5128db312db79 · Passage 89b004a4dcc1ebf70e22a81c16d6c68c59b3806a09934ac10f34f5e7ebe9ba01 · Zeichen 9739–10513 im Abschnitt
Nebenwirkungen · Dupixent
Dupixent 300 mg solution for injection in pre-filled syringe Dupixent 300 mg solution for injection in pre-filled pen · Abschnitt 4.8 · PDF-Seite 13
HOS-138358 · Präparat HOS-098186
Approximately 16 % of adolescent patients with atopic dermatitis who received dupilumab 300 mg or
200 mg Q2W for 16 weeks developed antibodies to dupilumab; approximately 3 % exhibited
persistent ADA responses, and approximately 5 % had neutralizing antibodies.
Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.
Vollständigen Kontext in der EMA-Fachinformation lesen →Quellennachweis
Version 2026-08-18T10:31:00Z · SHA-256 03cfef0820960157937161ad51a96760d9bff76c2f23c8cca9d5128db312db79 · Passage 303fdb048defe9ea92e4179a2d18c5d58dfd6b212153f22f03972ec4c6699cf5 · Zeichen 10515–10776 im Abschnitt
Nebenwirkungen · Dupixent
Dupixent 300 mg solution for injection in pre-filled syringe Dupixent 300 mg solution for injection in pre-filled pen · Abschnitt 4.8 · PDF-Seite 13
HOS-138359 · Präparat HOS-098186
Approximately 9 % of patients with asthma who received dupilumab 200 mg Q2W for 52 weeks
developed antibodies to dupilumab; approximately 4 % exhibited persistent ADA responses and
approximately 4 % had neutralizing antibodies.
Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.
Vollständigen Kontext in der EMA-Fachinformation lesen →Quellennachweis
Version 2026-08-18T10:31:00Z · SHA-256 03cfef0820960157937161ad51a96760d9bff76c2f23c8cca9d5128db312db79 · Passage 45008ce604908380f213b058611c2452672d02ee8c8678cf96b26033ce5fb857 · Zeichen 10778–11005 im Abschnitt
Nebenwirkungen · Dupixent
Dupixent 300 mg solution for injection in pre-filled syringe Dupixent 300 mg solution for injection in pre-filled pen · Abschnitt 4.8 · PDF-Seite 13
HOS-138360 · Präparat HOS-098186
Approximately 1% of patients 1 year of age and older with EoE who received dupilumab 300 mg QW
(≥40 kg), 300 mg Q2W (≥30 to <60 kg), 200 mg Q2W (≥15 to <30 kg), or 100 mg Q2W (≥5 to <15
kg) for 52 weeks developed antibodies to dupilumab; the ADA responses were neither persistent nor
neutralizing..
Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.
Vollständigen Kontext in der EMA-Fachinformation lesen →Quellennachweis
Version 2026-08-18T10:31:00Z · SHA-256 03cfef0820960157937161ad51a96760d9bff76c2f23c8cca9d5128db312db79 · Passage b624b86684db7707278a0ca70ef70aa892ec198b6740cdba47bb6acb6fb5bfb7 · Zeichen 11007–11305 im Abschnitt
Nebenwirkungen · Dupixent
Dupixent 300 mg solution for injection in pre-filled syringe Dupixent 300 mg solution for injection in pre-filled pen · Abschnitt 4.8 · PDF-Seite 13
HOS-138361 · Präparat HOS-098186
Approximately 8% of patients with COPD who received dupilumab 300 mg Q2W for 52 weeks
developed antibodies to dupilumab; approximately 3% exhibited persistent ADA responses and
approximately 3% had neutralizing antibodies.
Approximately 4.7% of adult patients with CSU who received dupilumab 300 mg Q2W and
adolescent patients with CSU who received dupilumab 300 mg or 200 mg Q2W for 24 weeks
developed antibodies to dupilumab; approximately 0.5% exhibited persistent ADA responses and
approximately 1% had neutralizing antibodies. No paediatric patients 2 to 11 years of age with CSU
who received dupilumab 200 mg Q4W, 300 mg Q4W, or 200 mg Q2W for 24 weeks developed a
positive ADA response to dupilumab.
Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.
Vollständigen Kontext in der EMA-Fachinformation lesen →Quellennachweis
Version 2026-08-18T10:31:00Z · SHA-256 03cfef0820960157937161ad51a96760d9bff76c2f23c8cca9d5128db312db79 · Passage 14b1121f145a3b84541a09cae2cfa369b7473b22b91352d7a2b21d05b873549c · Zeichen 11307–12013 im Abschnitt
Nebenwirkungen · Dupixent
Dupixent 300 mg solution for injection in pre-filled syringe Dupixent 300 mg solution for injection in pre-filled pen · Abschnitt 4.8 · PDF-Seite 13
HOS-138362 · Präparat HOS-098186
Regardless of age or population, up to 7 % of patients in the placebo groups were positive for
antibodies to dupilumab; up to 3 % exhibited persistent ADA response and up to 2 % had neutralizing
antibodies.
Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.
Vollständigen Kontext in der EMA-Fachinformation lesen →Quellennachweis
Version 2026-08-18T10:31:00Z · SHA-256 03cfef0820960157937161ad51a96760d9bff76c2f23c8cca9d5128db312db79 · Passage 69c9b22ceba13461560d921bdf1e438645f0076277637e477fd2ed08efff1211 · Zeichen 12015–12221 im Abschnitt
This product uses publicly available data from the U.S. National Library of Medicine (NLM), National Institutes of Health, Department of Health and Human Services; NLM is not responsible for the product and does not endorse or recommend this or any other product.